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Abstract
Purpose: The goal of the present study is to develop polymeric matrix films loaded with a
combination of free diclofenac sodium (DFSfree) and DFS:Ion exchange resin complexes (DFS:IR)
for immediate and sustained release profiles, respectively.
Methods: Effect of ratio of DFS and IR on the DFS:IR complexation efficiency was studied using
batch processing. DFS:IR complex, DFSfree, or a combination of DFSfree+DFS:IR loaded matrix
films were prepared by melt-cast technology. DFS content was 20% w/w in these matrix films.
In vitro transcorneal permeability from the film formulations were compared against DFS
solution, using a side-by-side diffusion apparatus, over a 6 h period. Ocular disposition of DFS
from the solution, films and corresponding suspensions were evaluated in conscious New
Zealand albino rabbits, 4 h and 8 h post-topical administration. All in vivo studies were carried
out as per the University of Mississippi IACUC approved protocol.
Results: Complexation efficiency of DFS:IR was found to be 99% with a 1:1 ratio of DFS:IR. DFS
release from DFS:IR suspension and the film were best-fit to a Higuchi model. In vitro
transcorneal flux with the DFSfree+DFS:IR(1:1)(1 + 1) was twice that of only DFS:IR(1:1) film. In vivo,
DFS solution and DFS:IR(1:1) suspension formulations were not able to maintain therapeutic DFS
levels in the aqueous humor (AH). Both DFSfree and DFSfree+DFS:IR(1:1)(3 + 1) loaded matrix films
were able to achieve and maintain high DFS concentrations in the AH, but elimination of DFS
from the ocular tissues was much faster with the DFSfree formulation.
Conclusion: DFSfree+DFS:IR combination loaded matrix films were able to deliver and maintain
therapeutic DFS concentrations in the anterior ocular chamber for up to 8 h. Thus, free drug/IR
complex loaded matrix films could be a potential topical ocular delivery platform for achieving
immediate and sustained release characteristics.
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Definition
Ion exchange resins $ Water insoluble cross linked
polymers with ionizable groups that can be exchanged to
form complexes. Ion exchange resin (IR) in the present study
represent DuoliteTM AP 143/1083.
DFS:IR(1:1) $ 1 part by weight of DFS is bound to 1 part by
weight of IR.
DFS:IR(1:2) $ 1 part by weight of DFS is bound to 2 part by
weight of IR.
DFS:IR(2:1)$ 2 part by weight of DFS is bound to or used to
form complexes with 1 part by weight of IR.
DFSfree Film$ Matrix film with unbound/free from of DFS
without any IR.
DFSfree+DFS:IR(1:1)(1+ 1) $ 1 part by weight of DFS is
bound to 1 part by weight of IR (for sustained release) and
remaining 1 part by weight of DFS is in unbound or free state
(DFSfree for immediate release). For example, in a film with
1.6 mg of total DFS, 0.8 mg DFS is as DFS-IR and remaining
0.8 mg of DFS is as DFSfree
.
DFSfree+DFS:IR(1:1)(3+ 1) $ 1 part by weight of DFS is
bound to 1 part by weight of IR (for sustained release) and
remaining 3 parts by weight of DFS is in unbound or free
state (DFSfree for immediate release). For example, in a film
with 1.6 mg of total DFS, 0.4 mg DFS is as DFS-IR and
remaining 1.2 mg of DFS is as DFSfree.
Introduction
Ion exchange resins (IR) are water insoluble cross-linked
polymers with ionizable groups that can be used to form
complexes (Guo et al., 2009). They are differentiated into
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anionic and cationic exchange resins based on the charge on
the exchangeable ionic group (Sriwongjanya & Bodmeier,
1998). The strong cation exchangers, such as AmberliteTM
IRP69, contain sulfonic acid functional groups, while the
weak cation exchange resins, such as AmberliteTM IRP64
and IRP88, contain carboxylic acid functional groups.
Similarly, anion exchange resins are also divided into
strong exchange resins, with quaternary ammonium groups
attached to the matrix such as DuoliteTM AP 143/1083
(Figure provided in supplemental data) and Amberlite IRA-
410, and weak anion exchangers such as Dowex WGR-2
and Amberlite IRA-67.
In the past, IRs were primarily used in the field of agriculture
and for the purification of water (Mantell, 1951). Application of
IRs as excipients in the field of medicine started when synthetic
ion-exchange resins were used as taste masking and as
stabilizing agents in oral dosage forms (Kankkunen et al.,
2002; Bhise et al., 2008; Patra et al., 2010; The Dow Chemical
Company). Moreover, drug-IR complexes show modified
release profiles when compared to the release of free drug
(Halder & Sa, 2006). Saunders and Srivatsava studied the
complexation efficiencies and release kinetics of alkaloids from
IRs and suggested that IRs can be used as suitable carriers for
the development of sustained-release formulations (Chaudhry
& Saunders, 1956). Sriwongjanya & Bodmeier (1998)
evaluated the complexation of propranolol hydrochloride and
diclofenac sodium (DFS; Figure provided in supplemental data)
with Amberlite IRP 69 and Duolite ATP 143, respectively.
These drug-IR complexes were loaded in hydroxypropyl
methyl cellulose (HPMC) matrix tablets to slow their release
and to achieve a sustained release profile. Release rates
depended on the amount, resin particle size and the type of
carrier. The authors observed that the pH of the dissolution
medium (0.1 N HCl or pH 7.4 phosphate buffer), or presence of
the counter ion, had little to no effect on the release rate from the
strong cation exchanger. With the weak cation exchange resin,
in situ complex formation and retardation was only observed in
pH 7.4 buffer but not in 0.1 N HCl because of the non-ionizable
carboxyl groups. The use of smaller resin particles eliminated
the burst release observed with the larger resin particles.
Modifying release rates has been one of the major
applications of ion exchange resins in the pharmaceutical
industry. Nicorette is a widely used product for smoking
cessation. It contains nicotine sorbed onto ion-exchange resin
in a gum base (Ove et al., 1975). The drug–resinate offers a
slower release profile for absorption over a 30-min period,
aided by the mechanical chewing activity and the slow elution
from the resin particles. Another example of controlled
release application is a liquid suspension product of
dextromethorphan called Delsym. Dextromethorphan is
bound to the ion-exchange resin and coated with ethylcellu-
lose (Amsel, 1980). The bioavailability of the product is
equivalent to that of dextromethorphan solution. Similarly,
ocular films have been studied before to establish a sustained
release profile employing their mucoadhesion mechanisms,
hydration or degree of swelling of the polymers (Lee et al.,
1999; Sasaki et al., 2003; Adelli et al., 2015). The uses of
films with ion-exchange resins in combination with free/
unbound drug and drug:IR complex, however, has not been
studied before.
The use of IRs in the field of ophthalmic formulations,
also has received little attention. Currently, Betoptic S
suspension containing 0.25% betaxolol HCl, is the only
ophthalmic product available that utilizes ion exchange
resins (Betoptic S). In the present study, we are using drug-
IR complexes loaded into polymeric melt cast films to
deliver DFS into the eye for prolonged periods. DFS belongs
to the class of drugs known as non-steroidal anti-inflamma-
tory drugs (NSAIDs) and is used to treat swelling (inflam-
mation) of the eye after cataract surgery (Herbort et al.,
2000). DFS is also used after corneal refractive surgery
(Fawzi et al., 2005) to temporarily relieve pain and
photophobia (sensitivity to light). One drop of the currently
marketed DFS ophthalmic solution formulation is applied
to the affected eye, four times daily, beginning 24 h after
cataract surgery and continued throughout the first two
weeks of the postoperative period (Bausch & Lomb).
Drug delivery to the eye has always been a challenging
task due to various physiological barriers (Lee & Robinson,
1986; Gaudana et al., 2010). Topical eye drops such as
solutions, gels and suspensions are the most accepted and
conventional drug delivery systems for treating ocular
diseases (Sharma et al., 2016). However, the ocular barriers
present major challenges when it comes to treating chronic
issues such as chronic inflammation, dry eye, uveitis, age
related macular degeneration, glaucoma and diabetic retin-
opathy (Edelhauser et al., 2010; Adelli et al., 2013). These
conditions require long-term therapy and frequent adminis-
tration of eye drops. Conventional drops deliver only 5–10%
of the applied dose into the anterior segment of the eye
because of precorneal drainage and other ocular barriers
(Geroski & Edelhauser, 2000; Gaudana et al., 2010). As a
result, the frequency of administration of the eye drops is
usually 4-6 times a day, as in the case of DFS ophthalmic
solution, based on the severity of the pathological condition.
For posterior segment diseases, eye drops are mostly
inefficient, so far, and although intravitreal injections are
very effective, they are associated with complications such
as pain, infection, endopthalmitis and retinal detachment
(Edelhauser et al., 2010).
Thus, there is an unmet need for novel and efficient
delivery strategies to prolong the duration of action of the
drug or drug candidates in the eye. Some of the delivery
systems currently under investigation include surface func-
tionalized nanoparticles (Kompella et al., 2013; Suk et al.,
2015; Wang et al., 2016), liposomes (Swaminathan &
Ehrhardt, 2012; Honda et al., 2013; Agarwal et al., 2016),
hydrogels (Li et al., 2013; Liang et al., 2016) and matrix films
(Maichuk Iu & Iuzhakov, 1994; Kaur & Kanwar, 2002; Adelli
et al., 2015; Maulvi et al., 2016). Amongst all the novel
formulation strategies being explored, melt-extruded matrix
films are the easiest to prepare and the fabrication process is
free of solvents or other additives that might cause unwanted
reactions at the site of application.
Thus, the objective of the present study is to evaluate
DFS:IR complex (Figure provided in supplemental data)
loaded polymeric matrix films for once or twice a day
application. Matrix films loaded with DFS unbound (DFSfree)
or DFS:IR complex or a combination of DFSfree and DFS:IR
complex (in various ratios) were examined with respect to
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DFS release profiles and ocular disposition following topical
application. DFS ophthalmic solution (marketed) and corres-
ponding IR suspensions were used as controls.
Methods
Chemicals
PEO [PolyOx WSR N-10 (PEO N-10), MW: 100 000 Da;
PubChem CID: 5327147] and DuoliteTM AP 143/1083
(Cholestyramine Resin USP; PubChem CID: 70695641)
were kindly donated by Dow Chemical Company (Midland,
MI). DFS (PubChem CID: 5018304) was purchased from
Sigma Aldrich (St. Louis, MO). Pearlitol 160 C was obtained
from Roquette Pharma as gift sample. DFS 0.1% w/v
ophthalmic solution (Akorn Pharmaceuticals, Lake Forest,
IL) was purchased from the pharmacy. All other chemicals
were purchased from Fisher Scientific (St. Louis, MO).
Animal tissues
Whole eye globes of New Zealand albino rabbits were
purchased from Pel-Freez Biologicals (Rogers, AK),
shipped overnight in Hanks Balanced Salt Solution over wet
ice (Majumdar et al., 2010) and used on the same day of
receipt.
Animals
Male New Zealand albino rabbits (2.0-2.5 kg) procured from
Harlan Laboratories (Indianapolis, IN) were used in all the
studies. All animal experiments conformed to the tenets of the
Association for Research in Vision and Ophthalmology
statement on the Use of Animals in Ophthalmic and Vision
Research and followed the University of Mississippi
Institutional Animal Care and Use committee approved
protocols (UM Protocol # 14-022).
Preparation of DFS-IR complex
Prior to complex formation, IRs were micronized and sieved
through a 400 US mesh size (Resin size537 microns) to
avoid any burst release from larger particles (Sriwongjanya
& Bodmeier, 1998). Then the resins were washed thoroughly
with deionized water and activated by washing with chloride
and hydroxide forms and then rinsed with water again.
The drug-resin complexes were formed by batch process
(The Dow Chemical Company, 2013). A concentrated
aqueous solution of DFS (20 mg/mL) was prepared. To
this, an accurately weighed amount of resin, three different
ratios of DFS:IR¼ 1:2, 1:1 or 2:1, was added and agitated
for 24 h. DFS:IR complexes (DFS:IR1:2, DFS:IR1:1 and
DFS:IR1:2) thus formed were separated out by centrifuga-
tion, washed with deionized water to remove unbound drug
and dried in a desiccator overnight.
To calculate the bound drug percentage, the supernatant
drug solution from the batch was collected before and after
the agitation process. The amount of DFS present in the
solution before and after the process were analyzed using
the HPLC-UV method. The complexed resins were
washed several times to remove any unbound or surface
adsorbed DFS.
Percentage drug bound was calculated by analyzing the
amount of drug remaining in the supernatant liquid and then
using Equation (1):
Percentage of bound drug ¼A1A2
A1
 100 ð1Þ
where A1¼ amount of DFS in initial aqueous solution (mg);
A2¼ amount of DFS in supernatant solution after 24 h (mg).
To confirm the complexation of DFS with IR, Fourier
transmission infrared (FTIR) spectra for IR, DFS and DFS:IR
complex were obtained using a Cary 660 series FTIR (Agilent
Technologies, Santa Clara, CA) and MIRacle Single
Reflection ATR (PIKE Technologies, Madison, WI).
Preparation of polymeric matrix film and IR
suspension
The melt-cast technology was employed in the preparation of
the polymeric matrix film following a previously published
protocol (Adelli et al., 2015). All matrix films were prepared
with a 20% w/w DFS load. Briefly, DFSfree and/or DFS:IR
complex was mixed with PEO N10 (geometric dilutions) to
obtain a uniform physical mixture. A 13 mm die was placed
over a brass plate and heated to 70 C using a hot plate. The
physical mixture (200 mg) was added to the center of the die
and compressed. The mixture was further heated for 2–3 min.
After cooling, 4 mm 2 mm sections, each weighing approxi-
mately 8 mg and with a drug load of 1.6 mg, were cut out from
the film.
IR suspension was prepared by first dissolving the free
DFS part in water (pH 7.2). Then, an accurately weighed
amount of DFS:IR was added to the solution. Mannitol 4.5%
w/v (Pearlitol 160 C) was added as tonicity adjusting agent.
To this, 0.5% HPMC (4000 cps) was added as a suspending
agent and kept under stirring until all the HPMC dissolved.
The pH of the formulation was adjusted to 7.3 using 0.1 N
hydrochloric acid and/or sodium hydroxide.
Assay and content uniformity
To determine the assay and content uniformity, a 1:1 mixture
of isotonic phosphate buffered saline at pH 7.4 and dimethyl
sulfoxide was used (The Dow Chemical Company, 2013).
Each 8 mg film segment was placed in 50 mL of medium, to
allow extraction of DFS from the resin, and sonicated for
15 min. This cloudy suspension was kept under constant
stirring for 2 h, to allow complete release of the complexed
drug, and centrifuged at 13 000 rpm for 15 min. The
supernatant was filtered through 0.2 m filter and analyzed
for free drug using the HPLC-UV method.
Scanning electron microscopy
The films (PEO N10, DFSfree and DFSfree + DFS:IR1:1(3 + 1))
were mounted on aluminum stubs using glued carbon tabs and
then sputter coated for 120 s with gold using a Hummer 6.2
sputter coater (Anatech USA, Union City, CA). During the
process, the gas pressure was at about 100 mTorr and the
current was 15 mA. The surface morphology of the prepared
samples was examined and digital micrographs were prepared
using a JSM-5600 Scanning Electron Microscope (JEOL USA
Inc., Peabody, MS) at an accelerating voltage of 5 kV.
372 G. R. Adelli et al. Drug Deliv, 2017; 24(1): 370–379
In vitro release and corneal permeability studies
To study the release profile of DFS from the various
formulations, Slide-A-Lyzer dialysis MINI devices
(10 000 Da MWCO) were used. A 20 mL glass vial was
filled with 18 mL of release media (IPBS pH 7.34) and a
magnetic stirrer was added to maintain equilibrium. Films
(20%w/w DFS loading; Dose: 1.0 mg) loaded with DFS-IR1:1
or with DFSfree + DFS:IR1:1(1 + 1) were placed in each
dialysis device. Hundred microliters of IPBS was added in
the dialysis device to wet the film. Similarly, in three more
sets (n¼ 3), 1 mL of 0.1%w/v DFS ophthalmic solution
(marketed formulation), DFS:IR(1:1) suspension and
DFSfree + DFS:IR1:1(1 + 1) suspension (Dose: 1 mg) was
added, to delineate the effect of the polymer matrix on the
release profile. The glass vials were placed over a magnetic
plate. The temperature was maintained at 34 ± 2 C using
calibrated hot plates. Aliquots, 0.8 mL, were collected at
specific time intervals and replaced with an equal volume of
release media. Studies were carried out for a period of 24 h.
Samples were analyzed using a HPLC-UV method. The
results from the studies were fit into zero order, first order,
Higuchi and Boyd model.
Similar studies were carried out with DFSfree +
DFS:IR1:1(1 + 1) to evaluate the effect of temperature (34
and 25 C) and pH (0.1 N HCl, and water) and compared with
the release profiles of DFS in IPBS pH 7.34 at 34 ± 2 C.
These studies were carried out for 12 h.
In vitro corneal flux and permeability of DFS from the
DFS:IR complex loaded film formulation was evaluated
using a side-by-side diffusion apparatus (PermeGear, Inc.,
Hellertown, PA) over a period of 6 h. The studies were carried
out by sandwiching the film (4 mm  2 mm; 20%w/w DFS;
weighing 8 mg approximately; Dose: 1.6 mg) in between a
Spectra/Por membrane (MWCO: 10 000 Da) and isolated
rabbit cornea (Pel-Freez Biologicals; Rogers, AK). Corneas
were excised from whole eye globes, following previously
published protocols (Majumdar et al., 2009, 2010). The
membrane-film-cornea sandwich was then positioned in
between the side-by-side diffusion cells (the chamber towards
the Spectra/Por membrane representing the periocular sur-
face and the chamber towards the cornea representing the
aqueous humor). Three milliliters (3 mL) of phosphate buffer,
pH 7.4, was added to the periocular side and 3.2 mL was added
to the aqueous humor side. Both chambers were sampled to
evaluate the periocular loss and corneal permeation.
A different set-up was used to study transcorneal flux from
the suspension and solution formulations. In this case, the
cornea was mounted in between the two half-cells (membrane
was not used in this case), 3 mL of DFS control solution or
DFS:IR(1:1) complex suspension was added to the donor
chamber. Phosphate buffer was used as receiver media
(3.2 mL).
In all cases, the side-by-side diffusion cells were main-
tained at 34 C using a circulating water bath. Six hundred
microliters aliquots were collected from the receiver cham-
ber(s) at specific time intervals and analyzed using the HPLC
method.
In vivo bioavailability studies
Male New Zealand albino rabbits weighing between 2.0 and
2.5 kg were used to determine in vivo ocular bioavailability of
DFS from the topically instilled formulations. In these studies,
20%w/w DFSfree and/or DFS:IR complex loaded films (weight
8 mg; dose: 1.6 mg) were placed in the conjunctival sac of the
rabbit eye, while 1.6%w/v DFS:IR suspension (volume:
0.1 mL and dose: 1.6 mg) was administered in the eye.
Hundred microliters of the 0.1% w/v DFS ophthalmic solution
was administered twice with half an hour gap between the two
applications (at -30 and 0 min; total dose: 200mg).
Initially, studies were carried out for a period of 4 h post-
application, with 0.1% w/v DFS ophthalmic solution,
DFSfree + DFS:IR(1:1)(3 + 1) film and DFSfree film. DFS
ophthalmic solution (0.1% w/v) was used to understand
ocular bioavailability of DFS from the solution formulation.
Based on the 4 h data, another set of in vivo studies,
evaluating ocular tissue concentrations 8 h post-topical
administration, was undertaken using the following formula-
tions: DFSfree + DFS:IR(1:1)(3 + 1) suspension, DFSfree +
DFS:IR(1:1)(3 + 1) matrix films and DFSfree loaded films.
The compositions of all the formulations used in the in vivo
studies are presented in Table 1. At the end of 4 h and 8 h,
post-application of the last dose, the rabbits were euthanized
under deep anesthesia with an overdose of pentobarbital
injected through the marginal ear vein. The eyes were washed
with ice cold IPBS and immediately enucleated and washed
again. Ocular tissues were carefully isolated, weighed and
preserved at 80 C until further analysis.
Table 1. Composition of various formulations of Diclofenac sodium (DFS) used for ocular disposition studies.
Formulations Formulation #1 Formulation #2 Formulation #3 Formulation #4
Ingredients 0.1% DFS ophthalmic
solution
DFSfree+DFS:IR(1:1)(3 + 1)
suspension
DFSfree film DFSfree+DFS:IR(1:1)
(3 + 1) film
Diclofenac sodium 10 mg 120 mg 1.6 mg 1.2 mg
DFS-IR::1:1 complex – 80 mg – 0.8 mg
Boric acid ˇ – – –
Edetate Disodium 10 mg – – –
Polyxyl 35 Castor Oil ˇ – – –
Sorbic acid 20 mg – – –
Tromethamine ˇ – – –
Mannitol – 450 mg – –
HPMC – 10 mg – –
PEO N10 – – 6.4 mg 6 mg
Water 10 mL 10 mL – –
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Analytical procedure for in vitro samples
Waters HPLC system with 600 E pump controller, 717 plus
auto sampler and 2487 UV detector was used. Data handling
was carried out using an Agilent 3395 integrator. A 40:60
mixture of water (pH 3.5–4.0) and ACN was used as the
mobile phase with Phenomenex Luna 5 mm C18 100 A˚,
250 4.6 mm column at a flow rate of 1.5 mL/min and
276 nm. DFS stock solution was prepared in mobile phase.
Bio-analytical method
Standard solution preparation
To 100 mL of aqueous humor (AH) or 500mL of vitreous
humor (VH) and to a weighed amount of the cornea, sclera,
iris ciliary bodies (IC) and retina-choroid (RC) tissues, 20 mL
of DFS stock in mobile phase (0.5, 1, 2.5, 5, 7.5 and 10mg/mL)
was added, vortexed and allowed to stand for 5 min. To
precipitate the proteins, ice cold ACN was added to the AH
and VH standards in a 1:1 ratio while 1 mL ACN was added to
the cornea, sclera, IC and RC standards. Final concentrations
of the standard solutions were in the range of 10–200 ng/mL
for AH; 10–100 ng/mL for VH; 20–200 ng/mL: cornea and
sclera and 10–200 ng/mL: IC and RC. Blanks were prepared,
to test for specificity, for all the tissues by adding 20 mL of
mobile phase instead of standard stock solutions to the
respective tissues and following the same protocol. All
samples were centrifuged at 13 000 rpm and 4 C for 30 min
and the supernatant was analyzed using HPLC-UV. All the
standard curves generated an R2 value greater than 0.97.
Sample preparation
Approximately, 0.1 mL of AH and 0.5 mL of VH was
collected from each test eye into individual centrifugal
tubes. All other tissues, RC, IC, cornea and sclera, from
each test eye were collected and weighed. Tissues were cut
into very small pieces and placed into individual vials.
Sample preparation and protein precipitation were carried out
similar to the standard solution preparation protocol and the
supernatant was analyzed using the HPLC-UV method.
A mixture of water (pH 3.5) and ACN in a ratio of 65:35
was used as the mobile phase with Phenomenex Luna 5 mm
C18 100 A˚, 250 4.6 mm column at a flow rate of 1 mL/min
and 284 nm.
Data analysis
All experiments were carried out at least in triplicate. DFS
release data were fitted to zero order, first order, Higuchi
models and Boyd models (Equations 2, 3, 4 and 5).
Ct¼ C0þK0t ð2Þ
LogCt¼ LogC0þKt=2:303 ð3Þ
Ct¼ KHt1=2 ð4Þ
where,
C0 and Ct¼concentration at time 0 min and t min; K0, K
and KH¼kinetic constants for zero order, first order and
Higuchi models.
ln 1Fð Þ¼ 3Pt=r ð5Þ
where, P is the apparent permeability of the film, F is fraction
of drug released after time t and r is the thickness of the resin
particles. The plot -ln(1-F) versus t provides a linear line with
a kinetic constant and coefficient correlation (R2).
Drug diffusion parameters across cornea such as rate (R)
and flux (J) were calculated using previously described
method (Majumdar & Srirangam, 2009).
Statistical analysis was carried out using ANOVA to
compare between different groups and Tukey’s post-hoc HSD
was used to compare differences between two groups. A
p value less than 0.05 was considered to denote statistically
significant difference.
Results
Complexation efficiency
DFS was complexed at different ratios with DuoliteTM AP 143
(1:1, 1:2 and 2:1). When the amount of DFS:IR was 2:1, only
49.3 ± 3.9% of DFS complexation was attained. At 1:1 and
1:2 ratios of DFS:IR a complexation efficiency of 99.03 and
99.04%, respectively, was achieved in both cases. Thus, all
further studies using complexed DFS employed a 1:1 ratio of
DFS and IR (DFS:IR(1:1)).
FTIR spectra shows DFS binds to Duolite AP143
(Figure 1). Characteristic peak of DFS at 3430.5 cm1 (N-H
stretching), 1573.5 cm1 (N-H bending) and 748.12 cm1
(C-Cl stretching) were observed in the FTIR spectra.
DuoliteTM AP 143 displays broad peak at about 3400 cm 1
corresponding to the quaternary ammonium bending vibra-
tion, peaks at 2850 to 2900 cm1 were corresponding to CH,
CH2 and CH3 stretching vibrations and two bands at 1600 and
1500 cm1 were corresponding to the aromatic ring. The N-H
bending and C-Cl stretching were observed in DFS-IR
complex demonstrating no covalent interaction between the
drug and IR. The characteristic N-H stretching of DFS and the
quaternary ammonium bending of Duolite resin can be
observed in the DFS:IR spectra indicating the complexation
between the resin and the drug (Figure 1).
Assay and content uniformity
DFS content in all the formulations was between 94 and 103%
of the theoretical values. DFS was found to be uniformly
distributed within the matrix film (RSD52.3%).
Scanning electron microscopy
Scanning electron microscopy images of the PEO N10,
DFSfree and DFSfree + DFS:IR1:1(3 + 1) films did not show any
significant differences. The pores observed in the films
facilitated the entry of water or the dissolution media for easy
and rapid disintegration of the films (Figure 2).
In vitro release and corneal permeability studies
Release of DFS, across the membrane, from the 0.1% w/v
ophthalmic solution was 80% within 6 h. Percent release of
DFS from DFS:IR(1:1) complex and DFSfree + DFS:IR(1:1)
(1 + 1) suspensions was 48.8 ± 2.3 and 72.4 ± 2.9, respect-
ively, in 24 h. With the DFS:IR(1:1) complex and
DFSfree + DFS:IR(1:1)(1 + 1) loaded matrix films, 52.7 ± 4.9
and 75.5 ± 3.8 percent of the DFS, respectively, was released
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across the membrane in 24 h (Figure 3). DFS release kinetics
from each formulation is presented in Table 2. Percentage
release of DFS from DFSfree + DFS:IR(1:1)(1 + 1) loaded
matrix films in 0.1 N HCl and water were 0.7 ± 0.07% and
1.09 ± 0.7%, respectively. Percentage release of DFS from
DFSfree + DFS:IR(1:1)(1 + 1) loaded films at 25
C in IPBS
was 23.0 ± 2.2% compared to 60.2 ± 3.5% release at 34 C at
the end of 12 h.
Transcorneal flux from the various formulations was
10.2 ± 0.2 (0.1% w/v DFS ophthalmic solution), 2.0 ± 0.9
(DFSfree matrix film), 0.34 ± 0.04 (DFS:IR(1:1) suspension),
0.4 ± 0.05 (DFS:IR(1:1) film) and 0.7 ± 0.04 (DFSfree +
Figure 1. FTIR spectra of DFS, DuoliteTM AP 143/1083 (IR) and DFS:IR complex.
Figure 2. SEM of PEO N10, DFSfree and DFSfree + DFS:IR1:1(3 + 1) films at 25, 70 and 300 magnification.
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DFS:IR(1:1) (1:1) film) mg/min/cm
2. Rate of permeability of
DFS from the various formulations was 6.5 ± 0.1 (0.1% w/v
DFS ophthalmic solution), 1.3 ± 0.05 (DFSfree matrix film),
0.24 ± 0.02 (DFS:IR(1:1) suspension), 0.26 ± 0.04 (DFS:IR(1:1)
film) and 0.46 ± 0.02 (DFSfree + DFS:IR(1:1) (1:1) film)
mg/min.
DFS flux across the Spectra/Por membrane (representing
the precorneal loss) was 3.0 ± 0.2 and 5.5 ± 0.6 mg/min/cm2
from the DFS:IR(1:1) film and DFSfree + DFS:IR(1:1)(1 + 1)
film, respectively, under the settings employed.
In vivo studies
Initially, ocular tissue concentrations were evaluated 4 h post-
topical application of the DFS formulations. Ocular tissue
DFS concentrations were analyzed only in the anterior
segment of the eye (AH and IC) in this case. With the 0.1%
w/v DFS ophthalmic solution, 181.4 ± 64.8 and
932.4 ± 422.0 ng of DFS/gm of tissue was detected in the
AH and IC, respectively, at the end of 4 h. DFSfree films was
able to deliver 2.68 ± 0.2 mg and 2.7 ± 0.06mg DFS/gm of
tissue to the AH and IC, respectively. DFS:IR(1:1) complex
loaded films delivered lower amounts of DFS to the anterior
segment of the eye (0.9 ± 0.2 and 1.02 ± 0.05mg of DFS/gm
of tissue to AH and IC, respectively) due to presence of DFS
in the complexed form only.
To evaluate the sustained release effect of the matrix film
with the DFS-IR complex, an 8 h study was undertaken. The
ocular tissue concentrations obtained with the three formu-
lations tested are presented in Table 3. At an equivalent dose,
the IR suspension formulation delivered much lower concen-
trations than the IR-loaded film. DFS levels were below the
limit of detection in the VH with all the formulations tested.
Results from in vivo studies are presented in Table 3.
Discussion
Use of IRs in the field of drug delivery as taste masking and
controlled release excipients has been reported. Recently,
IRs have also been used in ophthalmic dosage forms to
achieve sustained release profiles and improved bioavail-
ability. Jani et al. (1994) developed a suspension formulation
of betaxalol hydrochloride (Betoptic S) by binding it to
IRs. Betoptic S retards drug release in the tear, increases
retention at the ocular surface and enhances drug bioavail-
ability. As a result, Betoptic S 0.25% is found to be
bioequivalent to Betoptic Solution 0.5% in terms of lowering
of intraocular pressure.
Figure 3. Percentage release of DFS up to
24 h form various ion exchange resin formu-
lations and marketed ophthalmic solution.
Table 2. Model parameters obtained from fitting DFS release data to zero order, first order, Higuchi and Boyd models.
Formulation Rate order Zero First Higuchi Boyd
DFS:IR(1:1) Suspension Kinetic constant 2.0547 0.012 10.891 0.1195
Coefficient correlation 0.9273 0.9688 0.9894 0.9903
DFSfree+DFS:IR(1:1)(1 + 1) Suspension Kinetic constant 3.0905 0.0237 16.681 0.1393
Coefficient correlation 0.8874 0.9671 0.9871 0.9959
DFS:IR(1:1) Film Kinetic constant 2.1577 0.013 11.639 0.119
Coefficient correlation 0.8973 0.9573 0.9913 0.9949
DFSfree+DFS:IR(1:1)(1 + 1) Film Kinetic constant 2.8066 0.0227 15.879 0.1294
Coefficient correlation 0.7871 0.9424 0.9567 0.9751
0.1% w/v ophthalmic solution Kinetic constant 3.9885 0.0961 23.449 0.1864
Coefficient correlation 0.6748 0.9895 0.8857 0.9687
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The goal of this project was to develop a matrix film
loaded with IRs to allow immediate and sustained release
profiles, thus providing both loading and maintenance
doses, by using a combination of free and complexed
drug in the matrix film. In the present study, an 8 mg
matrix film with a 20% w/w drug load (1.6 mg of drug)
was prepared. Of this 1.6 mg, 3 parts (1.2 mg) is maintained
in the uncomplexed state (DFSfree) for immediate release
and the other 0.4 mg (one part) is in the complexed state
(DFS:IR(1:1)) to provide the sustained release profile. The
matrix film polymer by itself adds to the sustained release
profile. The amounts of the free and bound DFS forms
loaded in the films can be modified to achieve the required
drug release profiles.
Duolite AP143 resin is an insoluble, strongly basic,
anion exchange resin, supplied as a dry powder. It is suitable
for use in pharmaceutical applications, both as an active
ingredient (for adsorption of toxic chemicals) and as a carrier
for acidic (anionic) drugs (Guo et al., 2009). Since DFS is
negatively charged in the solution, DFS forms a complex with
the positively charged Duolite AP143. In the present study,
we evaluated the complexation efficiency of DFS with the
resin at varying weight ratios of DFS and IR. No significant
difference was observed between DFS:IR(1:1) and DFS:IR(1:2)
in terms of complexation efficiency. Thus, all further studies
were carried out using the DFS:IR(1:1) complex. A combin-
ation of DFSfree and DFS:IR(1:1) was evaluated to provide
immediate and sustained release components.
In vitro release of DFS from DFS-IR complex formulations
showed an immediate release followed by a sustained release
profile. Eighty percent release was observed with the 0.1%
DFS ophthalmic solution within 6 h (102% in 24 h). With
DFSfree + DFS:IR(1:1)(1 + 1) combination in film, unbound
DFS was released in the first 2 h. Due to the equilibrium
between the bound and complexed form, sustained release of
the remaining DFS was observed from the complex in the
later part of the release profile. The initial release rate of DFS
from DFSfree + DFS:IR(1:1)(1 + 1) suspension formulation was
slower compared to that from the DFSfree + DFS:IR(1:1)(1 + 1)
film. This can be attributed to the greater concentration
gradient with the film than the suspension formulation. In the
film, the 1.6 mg of DFS is concentrated within a 4 mm 
2 mm surface area, while in a suspension it is distributed over
a greater surface area, thus reducing the concentration
gradient. DFS:IR(1:1) film and suspension showed approxi-
mately 33% less release compared to the
DFSfree + DFS:IR(1:1)(1 + 1) film and suspension. This is
because the total DFS exists in the complexed state in the
DFS:IR(1:1); the release was thus more sustained. The
DFS:IR(1:1) film showed slightly higher release rates than
the suspension, similar to the DFSfree + DFS:IR(1:1). The data
were fitted to zero order, first order and Higuchi kinetic
models. The 0.1% ophthalmic solution exhibited first-order
release kinetics with a coefficient of determination (R2) of
0.9895. All other formulations (DFS:IR(1:1) suspension,
DFS:IR(1:1) film, DFSfree + DFS:IR(1:1) suspension and
DFSfree + DFS:IR(1:1) film) were best fitted to the Boyd
model with R2 of 0.9903, 0.9959, 0.9949 and 0.9751,
respectively (Table 2). According to Boyd et al. (1947), the
drug release from ion exchange resinate can be controlled by
two kinds of diffusion processes, namely the diffusion of the
drug across the thin film at the periphery termed as film
diffusion and the diffusion of the drug in the matrix termed as
particle diffusion. The rate-controlling step is either diffusion
of drug across a thin liquid film at the periphery of the resin
particle or diffusion of freed drug in a matrix (Jeong et al.,
2007). From Table 2, we can see that in case of DFS:IR(1:1)
film diffusion gives better linearity indicating that it is the rate
limiting step. On the contrary, DFSfree + DFS:IR(1:1)(1 + 1)
particle diffusion was observed to be the rate limiting step due
to the presence of free drug.
Percentage release of DFS from
DFSfree + DFS:IR(1:1)(1 + 1) was very negligible in water
and in 0.1N HCl due to the absence of counter ions in the
release media. Percentage release of DFS at room temperature
(25 C) was less compared to the release at 34 C because of
polymer chain relaxation at higher temperature. This results
in faster gelation and drug release.
In vitro transcorneal permeability studies were performed
over a period of 6 h. With the DFS:IR(1:1) loaded film (total
1.6 mg in complexed state) flux across the isolated cornea was
approximately half of the flux obtained from the
DFSfree + DFS:IR(1:1)(1 + 1) loaded film. Presence of DFS in
the free state increased flux of DFS across the cornea.
Similarly, DFS flux from the DFSfree containing film was
higher than that of the DFSfree + DFS:IR(1:1)(1 + 1) film
formulation. With the DFSfree + DFS:IR(1:1) film, flux was
1/3rd of the flux obtained from the DFSfree film. This was
because the total dose (1.6 mg of DFS) was in unbound state.
In the case of the ophthalmic solution, the total DFS is in
solution resulting in high flux compared to all other
formulations.
Table 3. Ocular tissue DFS concentration (mg/g of tissue) obtained from various topical formulations of DFS.
Formulations (#)
Time (h) post
instillation Group # Cornea AH IC RC Sclera
0.1%w/v DFS solution (#1) 4 1 NA 0.18 ± 0.06 0.93 ± 0.4 NA NA
1.6%w/v DFSfree+DFS:IR(1:1)(3 + 1) suspension (#2) 8 2 1.3 ± 1.0 0.18 ± 0.07 0.43 ± 0.19 ND 8.4 ± 1.7
20%w/w DFSfree Film (#3) 4 3 NA 2.6 ± 0.2* 2.7 ± 1.1
b NA NA
8 4 7.5 ± 3.4 0.7 ± 0.06b 0.78 ± 0.35c ND 14.6 ± 4.8
20%w/w DFSfree+DFS:IR(1:1)(3 + 1) Film (#4) 4 5 NA 0.9 ± 0.2* 1.02 ± 0.05 NA NA
8 6 2.3 ± 1.4 0.36 ± 0.06a 0.66 ± 0.15c 0.09 ± 0.02 7.02 ± 4.03
AH - Aqueous humor, IC - Iris ciliary bodies, RC - Retina-choroid. NA - not analyzed, ND - below detection limit. Statistical significance was
calculated using Tukey HSD (IBM SPSS 23). *Significantly different from all groups, aSignificantly different from group #5, bSignificantly different
from all groups except group #5, cSignificantly different from group #3.
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Based on the in vitro release and permeability data, it was
apparent that the DFSfree + DFS:IR(1:1)(1 + 1) formulations
were retaining DFS for longer period of time - 50% DFS
release occurred in 12 h. In vivo studies were thus carried out
with three parts of DFSfree (1.2 mg) and one part (0.4 mg) as
DFS:IR(1:1), DFSfree +DFS:IR(1:1)(3 + 1), to allow faster
release of DFS from the combination matrix system. When
DFSfree + DFS:IR(1:1)(3 + 1) suspension was administered a
slight increase in the blinking rate was observed compared to
the ophthalmic solution. The DFSfree +DFS:IR(1:1)(3 + 1)
suspension formulation caused slight discomfort to the
rabbit eye. The polymeric matrix film formulations, however,
did not induce excessive tearing, redness or allergies as
reported in our previous study (Adelli et al., 2015). Ocular
discomfort was not observed with the
DFSfree + DFS:IR(1:1)(3 + 1) film also. This is probably
because the particles were embedded in the film and, thus,
did not cause any discomfort to the eye.
DFS ophthalmic solution was tested in vivo in the rabbits
to determine the DFS levels obtained in the ocular tissues
with the currently marketed formulations, in the experimental
model. Expectedly, with the 0.1% w/v ophthalmic solution,
DFS concentrations in the AH and IC were much lower at the
end of 4 h compared to other formulations tested. DFSfree
films, on the other hand, produced the highest concentrations
in the AH and IC. Concentration of DFS in AH from 0.1%
w/v ophthalmic solution was found similar to the data
presented by Li et al. (2012): approximately 0.1 mg at 4 h
post-topical application of 50 mL of 3.65 mg/mL of DFS
solution. The matrix film transforms into a gel and releases
the free drug much faster than that from the DFS:IR(1:1) or the
DFSfree + DFS:IR(1:1)(3 + 1) loaded films. As a result, we see
high DFS concentrations in the AH and IC from the DFSfree
films post topical application (4 h). In contrast, when the
DFSfree + DFS:IR(1:1)(3 + 1) loaded matrix film transforms
into a gel it starts releasing the free fraction of DFS, and,
simultaneously, the bound DFS is also exchanged for the
counter ions in the tear fluid releasing DFS from the
DFS:IR(1:1) complex. IRs have the ability to form in situ
complexes (Sriwongjanya & Bodmeier, 1998). As a result,
some of the free DFS again starts forming a complex to
maintain the binding equilibrium. Because of this constant
change in the equilibrium the ocular tissue levels obtained
from the DFSfree + DFS:IR(1:1)(3 + 1) film were lower com-
pared to the DFSfree film.
DFSfree and DFSfree + DFS:IR(1:1)(3 + 1) films were eval-
uated for ocular tissue distribution of DFS 8 h post-topical
administration. In addition to the films, DFSfree +
DFS:IR(1:1)(3 + 1) suspension (same dose) was also tested to
delineate the effect of the polymeric matrix film on the
disposition of DFS in the ocular tissues. When
DFSfree + DFS:IR(1:1)(3 + 1) suspension was administered,
AH DFS concentrations achieved were similar but DFS
concentrations were lower in the IC. This could be because of
higher precorneal loss with the suspension dosage form. At
the end of 8 h, the DFSfree film produced higher DFS levels in
the AH and IC compared to the DFSfree + DFS:IR(1:1)(3 + 1)
suspension or film. Importantly, the rate of elimination of
DFS from the ocular tissues between the 4 h and 8 h time
period, was much faster with the DFSfree film compared to the
DFSfree + DFS:IR(1:1)(3 + 1) film: 0.02375 and 0.0623mg/h,
respectively, from the AH. Similarly, the rate of elimination of
DFS from IC for DFSfree film and DFSfree + DFS:IR(1:1)(3 + 1)
film were 0.2347 and 0.0441 mg/h, respectively. Since there is
a constant release of DFS from DFS:IR(1:1), DFS absorption
phase was extended. As a result, rate of elimination from
these tissues was lower compared to the DFSfree film.
With the DFSfree + DFS:IR(1:1)(3 + 1) suspension, the DFS
concentration gradient build up was low and, thus, most of the
DFS was restricted to the cornea and sclera, the outermost
ocular tissues. At the end of 8 h, posterior segment ocular
tissues were also evaluated for DFS concentrations. None of
the formulations were able to deliver detectable DFS levels to
the VH. The DFSfree +DFS:IR(1:1)(3 + 1) film was able to
deliver low but detectable DFS levels to the RC
(89.2 ± 24.2 ng/g of tissue).
According to Blanco et al. (1999), half-maximal inhibitory
concentration (IC50) values of DFS for inhibiting COX-1 and
COX-2 enzymes is 0.611 mM (194.4 ng/mL) and 0.63 mM
(200.4 ng/mL), respectively. DFS concentrations obtained
from both solution and suspension formulations in the AH
were below IC50 levels. Both DFSfree and DFSfree +
DFS:IR(1:1)(3 + 1) loaded films were able to maintain signifi-
cant DFS levels in the ocular tissues even at the end of 8 h
post-topical application. Additionally, rate of elimination
from the inner ocular tissues with the DFS:IR film formula-
tion was significantly slower compared to the DFSfree films.
Thus, DFS:IR(1:1) loaded matrix films can maintain DFS
levels for prolonged periods of time and may allow at least
twice a day application. Moreover, the DFS:IR loaded dosage
forms avoids the DFS concentration spikes in the ocular
tissues noted with the other dosage forms including the
DFSfree loaded matrix films.
Conclusions
This is the first report, to the best of our knowledge,
investigating the effectiveness of an IR complex loaded
matrix film as a topical ocular drug delivery platform.
Ocular tissue DFS concentrations obtained from the matrix
films generated high concentrations in the AH and IC
bodies. Although, DFSfree film was able to produce high
DFS concentrations in the ocular tissues, DFS:IR film
showed more controlled release across the tissues.
Interestingly, only the DFS:IR film was able to deliver the
drug to the posterior segment of the eye (RC). Thus, drug-IR
complexes loaded into a matrix film can serve as a perfect
platform for both immediate and sustained release systems.
Modification of the IR film using different resins, different
ratios of free to bound drug concentrations and different
melt-extrudable polymer types can be used to achieve the
desired drug release profiles.
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